This is the text extract for April Tender Notification; Contact: Notifications; Posted: 2012-04-30, browse documents here.

---

30 April 2012

TENDER RESULTS

The PHARMAC Board (or Acting Chief Executive under Delegated Authority) has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2010/11 Invitation to Tender, dated 2 November 2010 and 2011/12 Invitation to Tender, dated 1 November 2011 As discussed in our 2010 tender consultation document, we are notifying tender decisions as they are made in 2012. This change is to provide maximum notification of upcoming changes to the market, specifically to incumbent suppliers. Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website – www.pharmac.govt.nz/schedule.asp. Where a product does not have a current pharmacode, suppliers are required to ensure a pharmacode has been issued by the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct pharmacode.

A504360 - qA21977

Page 1 of 7

---

2011/12 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2015 Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

Current subsidy and (price) $1.59 $21.10 $41.50 $6.43 $16.81 $10.75 $25.00 $5.95 $5.55 $8.95 New subsidy and price $0.59 $18.80 $34.25 $4.50 $11.77 $10.25 $25.00 $5.55 $5.55 $6.55

The decisions were as follows:

Chemical name Cyclizine hydrochloride Cyproterone acetate Cyproterone acetate Fentanyl citrate Fentanyl citrate Furosemide Furosemide Methadone hydrochloride Methadone hydrochloride Methadone hydrochloride

Presentation; Pack size and type Tab 50 mg; 10 tablets, blister pack Tab 50 mg; 50 tablets, blister pack Tab 100 mg; 50 tablets, blister pack Inj 50 µg per ml, 2 ml; 10 ampoules Inj 50 µg per ml, 10 ml; 10 ampoules Tab 40 mg; 1,000 tablets, HDPE bottle Tab 500 mg; 50 tablets, glass bottle Oral liq 2 mg per ml; 200 ml, HDPE bottle Oral liq 5 mg per ml; 200 ml, HDPE bottle Oral liq 10 mg per ml; 200 ml, HDPE bottle

Sole supply brand (Supplier) Nausicalm (AFT) Siterone (Rex Medical) Siterone (Rex Medical) Boucher and Muir (Boucher and Muir) Boucher and Muir (Boucher and Muir) Diurin 40 (Mylan) Urex Forte (Aspen) Biodone (Biomed) Biodone Forte (Biomed) Biodone Extra Forte (Biomed)

Date of subsidy change

Sole Subsidised Supply date

1 July 2012 1 August 2012 1 August 2012 1 July 2012 1 July 2012 1 July 2012 1 December 2012 1 July 2012 1 July 2012 1 July 2012

1 October 2012 1 November 2012 1 November 2012 1 October 2012 1 October 2012 1 October 2012 1 March 2013 1 October 2012 1 October 2012 1 October 2012

2.

Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

A504360 - qA21977

Page 2 of 7

---

Chemical Name

Presentation; Pack size and type Tab 50 mg; 90 tablets, blister pack Tab 100 mg; 90 tablets, blister pack Tab 0.5 mg; 2 tablets, glass bottle Tab 0.5 mg; 8 tablets, glass bottle Tab 200 mg; 100 tablets, HDPE bottle

Current New subsidy subsidy and and price (price) $16.50 $26.70 $16.50 $66.00 $116.00 $9.82 $15.83 $6.25 $25.00 $47.92 $18.71 per 120 capsules $28.91 per 120 capsules

Sole supply brand (Supplier) Accarb (Mylan) Accarb (Mylan) Dostinex (Pfizer) Dostinex (Pfizer) Entapone (Mylan) Oratane (Douglas) Oratane (Douglas)

Date of listing/subsidy change for tender winning brand 1 October 2012 1 October 2012 1 July 2012 1 July 2012 1 October 2012 1 November 2012 1 November 2012

Date of reference pricing of other listed brands 1 December 2012 1 December 2012 1 September 2012 1 September 2012 1 December 2012 1 November 2012 1 November 2012

Sole Subsidised Brand (Supplier) Supply date (and affected by delisting of other reference pricing listed brands) and delisting 1 March 2013 1 March 2013 1 December 2012 1 December 2012 1 March 2013 1 April 2013 1 April 2013 Glucobay (Bayer) Glucobay (Bayer) Arrow-Cabergoline (Arrow) Arrow-Cabergoline (Arrow) Comtan (Novartis) Oratane (Douglas) Oratane (Douglas)

Acarbose Acarbose Cabergoline Cabergoline Entacapone* Isotretinoin^ Isotretinoin^

Cap 10 mg; 120 capsules, $48.48 per blister pack 180 capsules Cap 20 mg; 120 capsules, $69.70 per blister pack 180 capsules $3.50 Solox

Lansoprazole

Cap 15 mg; 28 capsules, blister pack

$2.00 $3.27 Lanzol Relief $4.65 Solox $2.32 $4.34 Lanzol Relief

Solox (Douglas)

1 November 2012

1 January 2013

1 April 2013

Lanzol Relief (Mylan)

Lansoprazole

Cap 30 mg; 28 capsules, blister pack

Solox (Douglas)

1 November 2012

1 January 2013

1 April 2013

Lanzol Relief (Mylan)

* Brand Switch Fee of $5.50 will be payable for this product from 1 March 2013 until 1 June 2013 subject to implementation of the proposed Pharmacy Services Agreement. ^ Douglas’ brand of isotretinoin (Oratane) 120 pack size will be listed in Section B of the Pharmaceutical Schedule from 1 November 2012 and Douglas’ brand of isotertinoin (Oratane) 180 pack size will be delisted from 1 April 2013

A504360 - qA21977

Page 3 of 7

---

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

3. Tenders awarded to pharmaceuticals where no brand is listed.

Presentation; Pack size and type Tab 0.5 mg; 2 tablets, glass bottle Tab 0.5 mg; 8 tablets, glass bottle Hospital Supply Brand (Supplier) Dostinex (Pfizer) Dostinex (Pfizer) DV Limit 1% 1%

The decisions were as follows:

Chemical Name Cabergoline Cabergoline

Pack price $6.25 $25.00

Listing date 1 July 2012 1 July 2012

Hospital Supply Status date 1 September 2012 1 September 2012

4.

Tenders awarded to listed pharmaceuticals where only the current brand is listed.

Chemical Name Atracurium besylate Atracurium besylate Cyclizine hydrochloride Presentation; Pack size and type Inj 10 mg per ml, 2.5 ml; 5 ampoules Inj 10 mg per ml, 5 ml; 5 ampoules Tab 50 mg; 10 tablets, blister pack Tab 50 mg; 50 tablets, blister pack Tab 100 mg; 50 tablets, blister pack Inj 50 µg per ml, 2 ml; 10 ampoules Inj 50 µg per ml, 10 ml; 10 ampoules Tab 40 mg; 1,000 tablets, HDPE bottle Tab 500 mg; 50 tablets, glass bottle Inj 5 mg; 1 vial Current pack price $12.55 $26.04 $1.59 $21.10 $41.50 $6.43 $16.81 $10.75 $25.00 $170.00 New pack price $6.13 $9.19 $0.59 $18.80 $34.25 $4.50 $11.77 $10.25 $25.00 $100.00 Hospital Supply Brand (Supplier) Tracrium (GSK) Tracrium (GSK) Nausicalm (AFT) Siterone (Rex Medical) Siterone (Rex Medical) Boucher and Muir (Boucher and Muir) Boucher and Muir (Boucher and Muir) Diurin 40 (Mylan) Urex Forte (Aspen) Zavedos (Pfizer) DV Limit 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% Date of price change 1 July 2012 1 July 2012 1 July 2012 1 August 2012 1 August 2012 1 July 2012 1 July 2012 1 July 2012 1 December 2012 1 July 2012 Hospital Supply Status date 1 September 2012 1 September 2012 1 September 2012 1 October 2012 1 October 2012 1 September 2012 1 September 2012 1 September 2012 1 February 2012 1 September 2012

The decisions were as follows:

Cyproterone acetate Cyproterone acetate Fentanyl citrate Fentanyl citrate Furosemide Furosemide Idarubicin hydrochloride*

A504360 - qA21977

Page 4 of 7

---

Chemical Name Idarubicin hydrochloride* Methadone hydrochloride Methadone hydrochloride Methadone hydrochloride Vinorelbine** Vinorelbine**

Presentation; Pack size and type Inj 10 mg; 1 vial Oral liq 2 mg per ml; 200 ml, HDPE bottle Oral liq 5 mg per ml; 200 ml, HDPE bottle Oral liq 10 mg per ml; 200 ml, HDPE bottle Inj 10 mg per ml, 1 ml; 1 vial Inj 10 mg per ml, 5 ml; 1 vial

Current pack price $340.00 $5.95 $5.55 $8.95

$24.00 $120.00

New pack price $200.00 $5.55 $5.55 $6.55 $12.85 $64.25

Hospital Supply Brand (Supplier) Zavedos (Pfizer) Biodone (Biomed) Biodone Forte (Biomed) Biodone Extra Forte (Biomed) Navelbine (NZ Med & Sci) Navelbine (NZ Med & Sci)

DV Limit 1% 1% 1% 1% 1% 1%

Date of price change 1 July 2012 1 July 2012 1 July 2012 1 July 2012 1 July 2012 1 July 2012

Hospital Supply Status date 1 September 2012 1 September 2012 1 September 2012 1 September 2012 1 September 2012 1 September 2012

* The price and subsidy of idarubicin hydrochloride (PCT only) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 July 2012. The subsidy for idarubicin hydrochloride 1 mg for ECP in Section B of the Pharmaceutical Schedule will change from $37.74 per 1 mg to $22.20 per 1 mg from 1 July 2012. ** The price and subsidy of vinorelbine (PCT only) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 July 2012. The subsidy for vinorelbine 1 mg for ECP in Section B of the Pharmaceutical Schedule will change from $2.71 per 1 mg to $1.45 per 1 mg from 1 July 2012.

5.

Tenders awarded to listed pharmaceuticals where at least one other brand is listed.

Presentation; Pack size and type Tab 50 mg; 90 tablets, blister pack Tab 100 mg; 90 tablets, blister pack Tab 200 mg; 100 tablets, HDPE bottle Inj 20 mg per ml, 2 ml; 1 vial Current pack price $16.50 $26.70 $116.00 New pack price $9.82 $15.83 $47.92 Hospital Supply Brand (Supplier) Accarb (Mylan) Accarb (Mylan) Entapone (Mylan) Irinotecan Actavis 40 (Actavis) Irinotecan Actavis 100 (Actavis) DV Limit 1% 1% 1% Date of listing/price change for tender winning brand 1 October 2012 1 October 2012 1 October 2012 Hospital Supply Status date (and delisting of other listed brands) 1 December 2012 1 December 2012 1 December 2012 Brand (Supplier) to be delisted Glucobay (Bayer) Glucobay (Bayer) Comtan (Novartis) Irinotecan-Rex (Rex Medical) Irinotecan-Rex (Rex Medical)

The decisions were as follows:

Chemical Name

Acarbose Acarbose Entacapone

Irinotecan*

$41.00

$9.34

1%

1 September 2012

1 November 2012

Irinotecan*

Inj 20 mg per ml, 5 ml; 1 vial

$100.00

$23.34

1%

1 September 2012

1 November 2012

A504360 - qA21977

Page 5 of 7

---

Chemical Name

Presentation; Pack size and type Cap 10 mg; 120 capsules, blister pack Cap 20 mg; 120 capsules, blister pack

Current pack price $48.48 per 180 capsules $69.70 per 180 capsules $3.50 Solox

New pack price $18.71 per 120 capsules $28.91 per 120 capsules

Hospital Supply Brand (Supplier) Oratane (Douglas) Oratane (Douglas)

DV Limit 1% 1%

Date of listing/price change for tender winning brand 1 November 2012 1 November 2012

Hospital Supply Status date (and delisting of other listed brands) 1 January 2013 1 January 2013

Brand (Supplier) to be delisted Oratane (Douglas) Oratane (Douglas)

Isotretinoin^ Isotretinoin^

Lansoprazole

Cap 15 mg; 28 capsules, blister pack

$2.00 $3.27 Lanzol Relief $4.65 Solox $2.32 $4.34 Lanzol Relief

Solox (Douglas)

1%

1 November 2012

1 January 2013

Lanzol Relief (Mylan)

Lansoprazole

Cap 30 mg; 28 capsules, blister pack

Solox (Douglas)

1%

1 November 2012

1 January 2013

Lanzol Relief (Mylan)

* The price and subsidy of irinotecan (PCT only) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 September 2012. The subsidy for irinotecan 1 mg for ECP in Section B of the Pharmaceutical Schedule will change from $1.04 per 1 mg to $0.24 per 1 mg from 1 November. ^ Douglas’ brand of isotretinoin (Oratane) 120 pack size will be listed in Part II of Section H from 1 November 2012 and Douglas’ brand of isotertinoin (Oratane) 180 pack size will be reference priced to the new pack size from 1 November 2012 and delisted from 1 January 2013.

2010/11 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2014 Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

6. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows: Chemical Name Presentation; Pack size and type Tab 10 mg; 100 tablets, blister pack Current New subsidy subsidy and and price price $2.77 per 50 tablets $3.32 per 100 tablets Sole supply brand (Supplier) Arrow-Amitriptyline (Arrow) Date of listing/subsidy change for tender winning brand 1 September 2012 Date of reference pricing of other listed brands 1 November 2012 Sole Subsidised Brand (Supplier) Supply date (and affected by delisting of other reference pricing listed brands) and delisting 1 February 2013 Amirol (AFT)

Amitriptyline

A504360 - qA21977

Page 6 of 7

---

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

7. Tenders awarded to listed pharmaceuticals where at least one other brand is listed.

Presentation; Pack size and type Tab 10 mg; 100 tablets, blister pack Inj 30 mg per ml, 1 ml; 10 ampoules, Current pack price $2.77 per 50 tablets $44.00 per 5 ampoules New pack price Hospital Supply Brand (Supplier) DV Limit 1% Date of listing/price change for tender winning brand 1 September 2012 Hospital Supply Status date (and delisting of other listed brands) 1 November 2012 Brand (Supplier) to be delisted Amirol (AFT) Mayne (Hospira)

The decisions were as follows:

Chemical Name

Amitriptyline Ephedrine hydrochloride

$3.32 per Arrow-Amitriptyline 100 tablets (Arrow) $66.00 per 10 ampoules Max Health (Max Health)

1%

1 September 2012

1 November 2012

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

The PHARMAC Board (or Chief Executive under Delegated Authority) resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2011/12 Invitation to Tender, dated 1 November 2011:

Chemical Name Irinotecan Vinorelbine Mirtazapine Line Item (widened access) Inj 20 mg per ml, 2 ml (widened access) Inj 10 mg per ml, 1 ml Tab 15 mg Irinotecan Vinorelbine Chemical Name Line Item (widened access) Inj 20 mg per ml, 5 ml (widened access) Inj 10 mg per ml, 5 ml

For products included in the 2010/11 Invitation to Tender and 2011/12 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or Acting Chief Executive) approval. We will keep you informed of any updates regarding such tender products as decisions are made. If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.

A504360 - qA21977

Page 7 of 7